BMAL1 and neoplasm: Subsequent to the completion of tumor modeling, the mice were individually administered with venetoclax, dasatinib, and sorafenib.The administration of venetoclax, dasatinib, and sorafenib demonstrated significant efficacy in reducing tumor size in mice harboring BMAL1 knockdown cells.